Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Tatsukawa, Hideki ^a   Sano, Tetsuro ^b   Fukaya, Yayoi ^a   Ishibashi, Naoto ^b   Watanabe, Makiko ^b   Okuno, Masataka ^c   Moriwaki, Hisataka ^c   Kojima, Soichi ^a  

^a RIKEN   (Japan)

^b KOWA COMPANY LTD   (Japan)

^c GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC RETINOID; CASPASE 3; DIETHYLNITROSAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; RETINOID; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; 3,7,11,15-TETRAMETHYL-2,4,6,10,14-HEXADECAPENTAENOIC ACID; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; PERETINOIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RETINOIC ACID; RETINOID X RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CROSS LINKING; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; GENE SILENCING; GENETICS; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE; UPREGULATION;

ANIMALIA; MUS MUSCULUS; RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; DIETHYLNITROSAMINE; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GTP-BINDING PROTEINS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINOID X RECEPTOR ALPHA; SP1 TRANSCRIPTION FACTOR; TRANSGLUTAMINASES; TRETINOIN; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 78650936920     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-4     Document Type: Article

References (27)

1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36:S74-S83. 10.1002/hep.1840360710, 12407579.
2. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334:1561-1567. 10.1056/NEJM199606133342402, 8628336.
3. Takai K, Okuno M, Yasuda I, Matsushima-Nishiwaki R, Uematsu T, Tsurumi H, Shiratori Y, Muto Y, Moriwaki H. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 2005, 48:39-45. 10.1159/000082093, 15785088.
4. Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, Friedman SL, Kojima S. Phosphorylation of retinoid X receptor α at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001, 61:7675-7682.
5. Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL, Moriwaki H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 2003, 24:1353-1359. 10.1093/carcin/bgg090, 12807734.
6. Nakamura N, Shidoji Y, Moriwaki H, Muto Y. Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-α. Biochem Biophys Res Commun 1996, 219:100-104. 10.1006/bbrc.1996.0188, 8619789.
7. Shimizu M, Suzui M, Deguchi A, Lim JT, Weinstein IB. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin Cancer Res 2004, 10:1130-1140. 10.1158/1078-0432.CCR-0714-3, 14871993.
8. Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, Yasuda I, Yamada Y, Akita K, Sano T, Shimada J, Kojima S, Okano Y, Friedman SL, Moriwaki H. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology 2002, 36:1115-1124. 10.1053/jhep.2002.36369, 12395321.
9. Iismaa SE, Mearns BM, Lorand L, Graham RM. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 2009, 89:991-1023. 10.1152/physrev.00044.2008, 19584319.
10. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003, 4:140-156. 10.1038/nrm1014, 12563291.
11. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002, 27:534-539. 10.1016/S0968-0004(02)02182-5, 12368090.
12. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J 2002, 368:377-396. 10.1042/BJ20021234, 1223021, 12366374.
13. Tatsukawa H, Fukaya Y, Frampton G, Martinez-Fuentes A, Suzuki K, Kuo TF, Nagatsuma K, Shimokado K, Okuno M, Wu J, Iismaa S, Matsuura T, Tsukamoto H, Zern MA, Graham RM, Kojima S. Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology 2009, 136:1783-95. 10.1053/j.gastro.2009.01.007, 19208340.
14. Piedrafita FJ, Pfahl M. Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol Cell Biol 1997, 17:6348-6358. 232486, 9343396.
15. Shao RX, Otsuka M, Kato N, Taniguchi H, Hoshida Y, Moriyama M, Kawabe T, Omata M. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 2005, 128:86-95. 10.1053/j.gastro.2004.09.077, 15633126.
16. McEwen DG, Ornitz DM. Regulation of the fibroblast growth factor receptor 3 promoter and intron I enhancer by Sp1 family transcription factors. J Biol Chem 1998, 273:5349-5357. 10.1074/jbc.273.9.5349, 9478995.
17. Fujise K, Nagamori S, Hasumura S, Homma S, Sujino H, Matsuura T, Shimizu K, Niiya M, Kameda H, Fujita K. Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. Hepatogastroenterology 1990, 37:457-460.
18. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S, Bernabeu C. Transcriptional activation of endoglin and transforming growth factor-β signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 2002, 100:4001-4010. 10.1182/blood.V100.12.4001, 12433697.
19. Kageyama R, Merlino GT, Pastan I. Epidermal growth factor (EGF) receptor gene transcription. Requirement for Sp1 and an EGF receptor-specific factor. J Biol Chem 1988, 263:6329-6336.
20. Shimada J, Suzuki Y, Kim SJ, Wang PC, Matsumura M, Kojima S. Transactivation via RAR/RXR-Sp1 interaction: characterization of binding between Sp1 and GC box motif. Mol Endocrinol 2001, 15:1677-1692. 10.1210/me.15.10.1677, 11579201.
21. Kagawa M, Sano T, Ishibashi N, Hashimoto M, Okuno M, Moriwaki H, Suzuki R, Kohno H, Tanaka T. An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-α expression and cell proliferation. Carcinogenesis 2004, 25:979-985. 10.1093/carcin/bgh093, 14742314.
22. Kitadai Y, Yasui W, Yokozaki H, Kuniyasu H, Haruma K, Kajiyama G, Tahara E. The level of a transcription factor Sp1 is correlated with the expression of EGF receptor in human gastric carcinomas. Biochem Biophys Res Commun 1992, 189:1342-1348. 10.1016/0006-291X(92)90221-6, 1282800.
23. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V, Rosmorduc O. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005, 41:307-314. 10.1002/hep.20538, 15660382.
24. Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005, 43:661-669. 10.1016/j.jhep.2005.02.040, 16023762.
25. Fabbi M, Marimpietri D, Martini S, Brancolini C, Amoresano A, Scaloni A, Bargellesi A, Cosulich E. Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ 1999, 6:992-1001. 10.1038/sj.cdd.4400573, 10556977.
26. Yamaguchi H, Wang HG. Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol Cell Biol 2006, 26:569-579. 10.1128/MCB.26.2.569-579.2006, 1346894, 16382148.
27. Peng X, Zhang Y, Zhang H, Graner S, Williams JF, Levitt ML, Lokshin A. Interaction of tissue transglutaminase with nuclear transport protein importin-α3. FEBS Lett 1999, 446:35-39. 10.1016/S0014-5793(99)00018-6, 10100610.